Suvorexant for Alzheimer's Disease
(SToP-AD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
Will I have to stop taking my current medications?
The trial may require you to stop taking certain medications, especially if they interact with suvorexant or are sedating. It's best to discuss your current medications with the study team to see if any changes are needed.
How does the drug Suvorexant differ from other Alzheimer's treatments?
Who Is on the Research Team?
Brendan Lucey, MD
Principal Investigator
Washington Univeristy School of Medicine
Are You a Good Fit for This Trial?
This trial is for individuals aged 65 or older with early signs of Alzheimer's, as indicated by specific brain scan results and cognitive assessments. They must be able to consent and follow study procedures. Excluded are those with certain sleep disorders, severe health conditions, recent substance abuse, high alcohol intake, obesity (BMI >35), or on conflicting medications.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive suvorexant 20mg or placebo daily for two years to assess its effect on amyloid-β accumulation
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Suvorexant
Suvorexant is already approved in United States, Japan for the following indications:
- Insomnia characterized by difficulties with sleep onset and/or sleep maintenance
- Insomnia characterized by difficulties with sleep onset and/or sleep maintenance
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
Good Ventures Foundation
Collaborator
Merck Sharp & Dohme LLC
Industry Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University
Good Ventures
Collaborator